Table 1.
Baseline Characteristics
| FA (n = 101) | R 5 mg (n = 46) | R 5 mg + FA (n = 59) | R 10 mg (n = 39) | R 10 mg + FA (n = 55) | R 20 mg (n = 49) | R 20 mg + FA (n = 52) | Total (n = 401) | |
|---|---|---|---|---|---|---|---|---|
| Gender, n (%) | ||||||||
| F | 69 (68.3) | 30 (65.2) | 45 (76.3) | 23 (59.0) | 35 (63.6) | 26 (53.1) | 33 (63.5) | 261 (65.1) |
| M | 32 (31.7) | 16 (34.8) | 14 (23.7) | 16 (41.0) | 20 (36.4) | 23 (46.9) | 19 (36.5) | 140 (34.9) |
| Race, n (%) | ||||||||
| White | 94 (93.1) | 38 (82.6) | 54 (91.5) | 38 (97.4) | 51 (92.7) | 45 (91.8) | 49 (94.2) | 369 (92.0) |
| Black | 1 (1.0) | 5 (10.9) | 2 (3.4) | 1 (2.6) | 3 (5.5) | 4 (8.2) | 2 (3.8) | 18 (4.5) |
| Other | 6 (5.9) | 3 (6.5) | 3 (5.1) | 0 (0.0) | 1 (1.8) | 0 (0.0) | 1 (1.9) | 14 (3.5) |
| Ethnicity, n (%) | ||||||||
| Hispanic | 9 (8.9) | 2 (4.3) | 2 (3.4) | 3 (7.7) | 5 (9.1) | 0 (0.0) | 8 (15.4) | 29 (7.2) |
| Age, y | ||||||||
| Mean (SD) | 70.2 (4.13) | 70.5 (4.85) | 70.8 (5.08) | 68.9 (4.03) | 71.0 (4.76) | 70.2 (4.89) | 69.4 (4.31) | 70.2 (4.57) |
| Medical history, n (%) | ||||||||
| CAD | 21 (20.8) | 4 (8.7) | 12 (20.3) | 5 (12.8) | 8 (14.5) | 13 (26.5) | 7 (13.5) | 70 (17.5) |
| Hypertension | 69 (68.3) | 33 (71.7) | 51 (86.4) | 32 (82.1) | 39 (70.9) | 35 (71.4) | 35 (67.3) | 294 (73.3) |
| T2DM | 29 (28.7) | 16 (34.8) | 29 (49.2) | 15 (38.5) | 18 (32.7) | 14 (28.6) | 17 (32.7) | 138 (34.4) |
| Obesity | 18 (17.8) | 6 (13.0) | 14 (23.7) | 11 (28.2) | 12 (21.8) | 8 (16.3) | 9 (17.3) | 78 (19.5) |
| Metabolic syndromea | 62 (61.4) | 28 (60.9) | 49 (83.1) | 29 (74.4) | 38 (69.1) | 30 (61.2) | 37 (71.2) | 273 (68.1) |
Abbreviations: CAD, coronary artery disease; F, female; FA, fenofibric acid; M, male; R, rosuvastatin; SD, standard deviation; T2DM, type 2 diabetes mellitus.
a
Determined according to National Cholesterol Education Program Adult Treatment Panel III definition.3